About Infensa
Infensa is a company based in Sydney (Australia) founded in 2021.. Infensa has raised $15.6 million across 1 funding round from investors including Australian Unity. Infensa offers products and services including Cardiovascular Drugs. Infensa operates in a competitive market with competitors including Acticor Biotech, Basking Biosciences, 4TEEN4 Pharmaceuticals, AptaTargets and CeleCor Therapeutics, among others.
- Headquarter Sydney, Australia
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Infensa Bioscience Pty Ltd
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$15.6 M (USD)
in 1 rounds
-
Latest Funding Round
$15.6 M (USD), Series B
Jul 04, 2022
- Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Infensa
Infensa offers a comprehensive portfolio of products and services, including Cardiovascular Drugs. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Medications aimed at reducing mortality from heart attacks and strokes.
Funding Insights of Infensa
Infensa has successfully raised a total of $15.6M through 1 strategic funding round. The most recent funding activity was a Series B round of $15.6 million completed in July 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series B — $15.6M
-
First Round
First Round
(04 Jul 2022)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2022 | Amount | Series B - Infensa | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Infensa
Infensa has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Australian Unity. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Retail banking services are provided to Australian customers.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Infensa
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Infensa
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Infensa Comparisons
Competitors of Infensa
Infensa operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Acticor Biotech, Basking Biosciences, 4TEEN4 Pharmaceuticals, AptaTargets and CeleCor Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Immunotherapeutics are developed for ischemic stroke treatment using monoclonal antibodies.
|
|
| domain | founded_year | HQ Location |
Therapeutics for ischemic stroke treatment are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics and diagnostics for cardiovascular diseases are developed.
|
|
| domain | founded_year | HQ Location |
Provider of therapeutic solutions for ischemic diseases
|
|
| domain | founded_year | HQ Location |
POC subcutaneous injectable for myocardial infarction treatment is developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Infensa
Frequently Asked Questions about Infensa
When was Infensa founded?
Infensa was founded in 2021 and raised its 1st funding round 1 year after it was founded.
Where is Infensa located?
Infensa is headquartered in Sydney, Australia. It is registered at Sydney, New South Wales, Australia.
Who is the current CEO of Infensa?
Mark Smythe is the current CEO of Infensa.
Is Infensa a funded company?
Infensa is a funded company, having raised a total of $15.6M across 1 funding round to date. The company's 1st funding round was a Series B of $15.6M, raised on Jul 04, 2022.
What does Infensa do?
Infensa was founded in 2021 in Sydney, Australia, within the biotechnology sector. Peptide-based therapeutics targeting cardiovascular disorders are developed by the company. A lead compound, IB001, is provided as a selective inhibitor of human ASIC1a, by which neurons and heart muscle cells are protected from ischemic injury. Operations focus on advancing these compounds through research and development stages.
Who are the top competitors of Infensa?
Infensa's top competitors include Acticor Biotech, 4TEEN4 Pharmaceuticals and Basking Biosciences.
What products or services does Infensa offer?
Infensa offers Cardiovascular Drugs.
Who are Infensa's investors?
Infensa has 1 investor. Key investors include Australian Unity.